Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 13/20 | 0.60 |
| ▸ | PPARG | P37231 | 8/20 | 0.60 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5991816 | 1.00 | PPARA (0.60) | PPARAPPARGPPARDITGB3ITGA2B | |
| SCHEMBL601719 | 0.91 | PPARG (0.72) | PPARAPPARGPPARDITGB3ITGA2B | |
| SCHEMBL5393093 | 0.91 | PPARG (0.72) | PPARAPPARGPPARDITGB3ITGA2B | |
| SCHEMBL5991079 | 0.91 | PPARA (0.57) | PPARAPPARGPPARDITGB3ITGA2B | |
| SCHEMBL6818773 | 0.90 | PPARA (0.60) | PPARAPPARGPPARDITGB3ITGA2B | |
| SCHEMBL5994334 | 0.90 | PPARA (0.53) | PPARAPPARGPPARD | |
| SCHEMBL5992972 | 0.90 | PPARA (0.53) | PPARAPPARGPPARD | |
| SCHEMBL5991872 | 0.90 | PPARG (0.52) | PPARAPPARGPPARDCYP17A1 | |
| SCHEMBL5386839 | 0.86 | PPARA (0.71) | PPARAPPARGPPARDITGB3ITGA2B | |
| SCHEMBL6921681 | 0.86 | PPARA (0.54) | PPARAPPARGITGB3ITGA2BHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149614-A1 | Guanidine and amidine acid derivatives and analogs and methods of using the same | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | disclosed |
| US-7169810-B2 | Guanidine and amidine acid derivatives and analogs and methods of using the same | ASTRAZENECA AB (SE) | 2007-01-30 | — | — | US | disclosed |
| US-20060173204-A1 | New 3-aryl propionic acid derivatives and analogs | ANDERSSON KJELL | 2006-08-03 | — | — | US | disclosed |
| US-20040229949-A1 | New 3-aryl propionic acid derivatives and analogs | ANDERSSON KJELL (SE) | 2004-11-18 | — | — | US | disclosed |
| US-20040138300-A1 | Compounds | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | US | disclosed |
| EP-1237857-B1 | NEW PHENALKYLOXY-PHENYL DERIVATIVES | ASTRAZENECA AB (SE) | 2004-06-30 | — | — | EP | disclosed |
| EP-1084101-B1 | NEW 3-ARYL-2-HYDROXYPROPIONIC ACID DERIVATIVE III | ASTRAZENECA AB (SE) | 2004-03-10 | — | — | EP | disclosed |
| EP-1383739-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2004-01-28 | — | — | EP | disclosed |
| US-6630509-B2 | Pharmaceutical medication associated with insulin resistance; patient with prophylaxis conditions having reduced sensitivity to insulin | ASTRAZENECA AB (SE) | 2003-10-07 | — | — | US | disclosed |
| US-6630600-B1 | Intermediate for their manufacture, pharmaceutical preparations containing them and the use of the compounds in clinical conditions associated with insulin resistance. | ASTRAZENECA AB (SE) | 2003-10-07 | — | — | US | disclosed |
| US-20030018207-A1 | Phenalkyloxy-phenyl derivatives | ASTRAZENECA AB (SE) | 2003-01-23 | — | — | US | disclosed |
| WO-2002085844-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-31 | — | — | WO | disclosed |
| EP-1237857-A1 | NEW PHENALKYLOXY-PHENYL DERIVATIVES | AstraZeneca AB (SE) | 2002-09-11 | — | — | EP | disclosed |
| US-6362360-B1 | SENSITIZERS FOR INSULIN RESISTANCE AND ASSOCIATED CONDITIONS DYSLIPIDEMIA AND HYPERGLYCEMIA | ASTRAZENECA AB (SE) | 2002-03-26 | — | — | US | disclosed |
| WO-2001040170-A1 | NEW PHENALKYLOXY-PHENYL DERIVATIVES | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001040165-A1 | CRYSTALLINE FORM OF 3-{4-[2-(4-TERT-BUTOXYCARBONYLAMINOPHENYL)ETHOXY]PHENYL}-(S)-2-ETHOXY PROPANOIC ACID | ASTRAZENECA AB (SE) | 2001-06-07 | — | — | WO | disclosed |
| EP-1084101-A1 | NEW 3-ARYL-2-HYDROXYPROPIONIC ACID DERIVATIVE III | AstraZeneca AB (SE) | 2001-03-21 | — | — | EP | disclosed |
| EP-1084102-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | AstraZeneca AB (SE) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999062870-A1 | NEW 3-ARYL-2-HYDROXYPROPIONIC ACID DERIVATIVE III | ASTRAZENECA AB (SE) | 1999-12-09 | — | — | WO | disclosed |
| WO-1999062871-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | ASTRAZENECA AB (SE) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149614-A1 | Guanidine and amidine acid derivatives and analogs and methods of using the same | IAPP, GCG, GLP1R | PPARA 353/4885PPARG 237/4885PPARD 229/4885 |
| US-20040229949-A1 | New 3-aryl propionic acid derivatives and analogs | GPR119, INSR, IRS1 | PPARA 11/4885PPARG 22/4885PPARD 8/4885 |
| US-20040138300-A1 | Compounds | IAPP, GPR119, GCKR | PPARA 591/4885PPARG 287/4885PPARD 281/4885 |
| US-20060173204-A1 | New 3-aryl propionic acid derivatives and analogs | GPR119, INSR, IRS1 | PPARA 11/4885PPARG 22/4885PPARD 8/4885 |
| US-20030018207-A1 | Phenalkyloxy-phenyl derivatives | GPR119, INSR, IAPP | PPARA 74/4885PPARG 47/4885PPARD 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.